Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep806 | Pituitary: clinical | ECE2015

Psychological and neurocognitive evaluation in patients with pituitary adenoma

Sala Elisa , Zarino Barbara , Malchiodi Elena , Verrua Elisa , Carosi Giulia , Locatelli Marco , Rampini Paolo , Carrabba Giorgio , Spada Anna , Mantovani Giovanna

Reduced health-related quality of life (HRQoL) and impairment in neurocognitive functions are a possible complaint in patients with pituitary adenoma. Psychiatric comorbidities in Cushing’s disease are well known. However recent studies showed HRQoL reduction and psychiatric symptoms in patients with pituitary disease with or without hormonal excess. Aim of this study is to analyse HRQoL, psychiatric symptoms and neurocognitive functions in patients with pituitary adenoma...

ea0035p517 | Endocrine tumours and neoplasia | ECE2014

The effects of cAMP in different neuroendocrine tumorous cells: the role of Epac and PKA in cell proliferation and cell adhesion

Vitali Eleonora , Cambiaghi Valeria , Zerbi Alessandro , Peverelli Erika , Mantovani Giovanna , Loiarro Federica , Carnaghi Carlo , Spada Anna , Lania Andrea

cAMP is an ubiquitous second messenger that is implicated in the regulation of a wide variety of cell functions, including cell proliferation that is differently affected depending on the cell type. Although the effects exerted by cAMP were initially attributed to PKA activation, two exchange proteins directly activated by cAMP (Epac1/2) have been identified as cAMP targets able to mediate several cAMP effects. Aim of this study was to investigate the effect of cAMP on neuroen...

ea0035p845 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

NFPA and hypopituitarism: a retrospective analysis of 260 patients and focus on the prevalence of isolated hypoadrenalism

Carosi Giulia , Malchiodi Elena , Ferrante Emanuele , Sala Elisa , Verrua Elisa , Beck-Peccoz Paolo , Spada Anna , Mantovani Giovanna

Introduction: Non-functioning pituitary adenomas (NFPA) accounts for about 40% of all pituitary tumors. One or more anteropituitary deficiencies are present at diagnosis in 60–80% of NFPA. Hypopituitarism classically appears with the following order: GH→FSH/LH→TSH→ACTH. Aim of the study was to evaluate the incidence and the order of appearance of pituitary deficiencies in patients with NFPA.Materials and methods: We retrospectively...

ea0070aep591 | Pituitary and Neuroendocrinology | ECE2020

Assessment of hypercoagulability in patients with cushing syndrome before and after surgical cure

Liliana Serban Andreea , Tripodi Armando , Indirli Rita , Mantovani Beatrice , Sala Elisa , Padovan Lidia , Arosio Maura , Mantovani Giovanna , Ferrante Emanuele

Background: Patients with Cushing’s Syndrome (CS) have a high risk of venous thromboembolism (VTE) related to a hypercoagulable state. Previous studies showed increased levels of procoagulant factors but also an elevation of some of the anticoagulants factors and fibrinolytic enzymes. Once patients achieve disease remission, there is a significant decrease of some procoagulant factors but if these alterations are completely reversible is still unclear. Compared to tradit...

ea0070aep694 | Pituitary and Neuroendocrinology | ECE2020

Micromegaly or acromegaly? A retrospective longitudinal study on clinical aspects and comorbidities in a large cohort of patients referred to a single tertiary center

Carosi Giulia , Sala Elisa , Mangone Alessandra , Del Sindaco Giulia , Mungari Roberta , Cremaschi Arianna , Ferrante Emanuele , Arosio Maura , Mantovani Giovanna

Introduction: The diagnosis of acromegaly is confirmed in the presence of high IGF-1 levels and inadequate suppression of growth hormone (GH) after glucose load. According to guidelines, a GH nadir (GHn)>0.4 ng/ml is considered diagnostic with ultrasensitive assays. However, some acromegalic patients with lower GHn, also called ‘micromegalic’, are reported, but a systematic collection of their clinical features is unavailable.Aim of the s...

ea0070aep724 | Pituitary and Neuroendocrinology | ECE2020

Metformin and everolimus: A promising combination for neuroendocrine tumors treatment

Vitali Eleonora , Boemi Ilena , Piccini Sara , Tarantola Giulia , Zerbi Alessandro , Smiroldo Valeria , Lavezzi Elisabetta , Spada Anna , Mantovani Giovanna , Lania Andrea

Treatment options for neuroendocrine tumors (NET), including everolimus, are rarely curative, as NETs frequently show resistance to medical therapy. In fact, the use of everolimus, an mTOR inhibitor, is limited by the development of resistance, probably due to the activation of Akt signalling. Metformin seems to have anticancer effects in neuroendocrine tumors (NETs). A recent retrospective study found longer progression-free-survival in diabetic pancreatic neuroendocrine tumo...

ea0032oc2.3 | Bone &amp; Calcium | ECE2013

Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series

Elli Francesca Marta , Barbieri Annamaria , Bordogna Paolo , Giardino Elena , Ferrante Emanuele , Beck-Peccoz Paolo , Spada Anna , Mantovani Giovanna

Progressive osseous heteroplasia (POH) is a rare autosomal dominant disorder of mesenchymal differentiation characterized by progressive heterotopic ossification (HO) of dermis, skeletal muscle and deep connective tissues. Initially HO occurs during infancy as osteoma cutis, then extends progressively into deep connective tissues during childhood. Most cases of POH are caused by paternally inherited mutations of GNAS gene. Maternal mutations as well as epigentic defec...

ea0032p824 | Pituitary–Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Role of filamin-A in the regulation of SST2 receptor localization and signalling in tumoral GH-secreting cells

Giardino Elena , Peverelli Erika , Vitali Eleonora , Cambiaghi Valeria , Lania Andrea G , Peccoz Paolo Beck , Mantovani Giovanna , Spada Anna

Somatostatin (SS) binds to different SS receptors (SSTR1–5) and SS analogues are the first choice medical treatment of GH-secreting pituitary adenomas (GH-omas). A subset of patients is resistant to SS, although the mechanisms involved in SS resistance are not fully understood. Recent studies identified specific protein–protein interactions as determinant in the regulation of receptor anchoring and signalling. Filamin A (FLNA) is a widely expressed cytoskeleton prote...

ea0022h2.2 | Oral Communications Highlights 2 | ECE2010

Human recombinant GH replacement therapy in children with pseudohypoparathyroidism type Ia and GH deficiency: first study on the effect on growth

Mantovani Giovanna , Ferrante Emanuele , Linglart Agnes , Cappa Marco , Cisternino Mariangela , Maghnie Mohamad , Beck-Peccoz Paolo , Spada Anna

Pseudohypoparathyroidism (PHP) refers to a heterogeneous group of rare metabolic disorders characterized by hypocalcemia and hyperphosphatemia due to PTH resistance. Heterozygous loss of function mutations in the gene encoding the alpha-subunit of Gs (GNAS) inherited from the mother lead to PHP type Ia. PHP type Ia (PHP-Ia) is a disease in which the physical features (short stature, obesity, round face, brachydactyly and subcutaneous ossifications) that constitute Albri...

ea0022oc1.5 | Diabetes and obesity | ECE2010

Role of PKA regulatory subunit R2B in murine and human adipocyte differentiation

Ermetici Federica , Peverelli Erika , Mantovani Giovanna , Corbetta Sabrina , Avagliano Laura , Bulfamante Gaetano , Beck-Peccoz Paolo , Spada Anna

PKA regulatory subunit 2B (R2B) is the most expressed in mouse adipose tissue, where it plays an important role in regulating energy balance. We previously demonstrated that R2B is the most abundant R subunit in human adult subcutaneous and visceral adipose tissues. We further showed that R2B expression and PKA activation are reduced in adipose tissues from obese as compared to non-obese subjects. Normal adipose tissue development and increases in fat mass associated with obes...